The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
Open accessAbstract
BACKGROUND: Familial combined hypolipidemia, a Mendelian condition characterized by substantial reductions in all 3 major lipid fractions, is caused by mutations that inactivate the gene angiopoietin-like 3 (ANGPTL3). Whether ANGPTL3 deficiency reduces risk of coronary artery disease (CAD) is unknown. OBJECTIVES: The study goal was to leverage 3 distinct lines of evidence-a family that included individuals with complete (compound heterozygote) ANGPTL3 deficiency, a population based-study of humans with partial (heterozygote) ANGPTL3 deficiency, and biomarker levels in patients with myocardial infarction (MI)-to test whether ANGPTL3 deficiency is associated with lower risk for CAD. METHODS: We assessed coronary atherosclerotic burden in 3 individuals with complete ANGPTL3 deficiency and 3 wild-type first-degree relatives using computed tomography angiography. In the population, ANGPTL3 loss-of-function (LOF) mutations were ascertained in up to 21,980 people with CAD and 158,200 control subjects. LOF mutations were defined as nonsense, frameshift, and splice-site variants, along with missense variants resulting in <25% of wild-type ANGPTL3 activity in a mouse model. In a biomarker study, circulating ANGPTL3 concentration was measured in 1,493 people who presented with MI and 3,232 control subjects. RESULTS: The 3 individuals with complete ANGPTL3 deficiency showed no evidence of coronary atherosclerotic plaque. ANGPTL3 gene sequencing demonstrated that approximately 1 in 309 people was a heterozygous carrier for an LOF mutation. Compared with those without mutation, heterozygous carriers of ANGPTL3 LOF mutations demonstrated a 17% reduction in circulating triglycerides and a 12% reduction in low-density lipoprotein cholesterol. Carrier status was associated with a 34% reduction in odds of CAD (odds ratio: 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04). Individuals in the lowest tertile of circulating ANGPTL3 concentrations, compared with the highest, had reduced odds of MI (adjusted odds ratio: 0.65; 95% confidence interval: 0.55 to 0.77; p < 0.001). CONCLUSIONS: ANGPTL3 deficiency is associated with protection from CAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, with genetic studies supporting the role of several novel therapeutic targets (eg, apo C-III and ANGPTL3) in atherosclerosis, ongoing clinical trials using RNA interference therapy (antisense oligonucleotides and small interfering RNAs) have the potential to further inform our understanding of the triglyceride-based atherosclerotic pathways (120,121).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [121]
The cited source says what the claim attributes to it.
In the citing paper
“Carriers of loss-of-function (LOF) variants in ANGTPL3 present with low triglyceride, low LDL (low-density lipoprotein) cholesterol (LDL-C), and low HDL (high-density lipoprotein) cholesterol (HDL-C) plasma levels,1 as well as a decreased risk for cardiovascular disease compared with non-carriers.2,3”
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
In the citing paper
“Loss-of-function variants in ANGPTL3 have been associated with reduced plasma levels of TG, LDL-C, and HDL-C.32,64,65”
In the citing paper
“individuals with ANGPTL3 LOF variants have low levels of TG, LDL-C, and HDL-C.32,65”
In the citing paper
“These hypotriglyceridaemic states contrast with mild HTG and increased ASCVD risk seen with heterozygous LOF mutations in APOA5.11”
From Clinical review on triglycerides (2020) · cites this paper as [11]
In the citing paper
“Similarly, heterozygous LOF variants in ANGPTL311 and ANGPTL412 genes are associated with reductions both in plasma TG and ASCVD risk.”
From Clinical review on triglycerides (2020) · cites this paper as [11]
In the citing paper
“ANGPTL3 is a genetically validated target for HTG to reduce ASCVD risk.11,77–79”
From Clinical review on triglycerides (2020) · cites this paper as [11]
In the citing paper
“Recently, the EpanoVa fOr Lowering Very high triglyceridEs II (EVOLVE II) trial confirmed the efficacy of omega-3 fatty acids in lowering serum TGs [327].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [327]
In the citing paper
“Genetic loss-of-function variants in ANGPTL3 are associated with lower levels of plasma lipids.”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Self-citationGenomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
Self-citationGenetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Self-citationLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Self-citationTobin, M. D., Sheehan, N. A., Scurrah, K. J., & Burton, P. R. (2005) · Statistics in Medicine · doi:10.1002/sim.2165 · Cited by 695
Flagged first, then by citations
1 of the 45 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 470
Khoury, É., Croteau, L., Lauzière, A., & Gaudet, D. (2022) · Future Cardiology · doi:10.2217/fca-2021-0149 · Cited by 8
Genetics-based risk scores for prediction of premature coronary artery disease
Gupta, R. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.08.003 · Cited by 7
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
Jain, V., Rifai, M. A., Mahtta, D., Liu, J., Hussain, A., & Virani, S. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00952-1 · Cited by 7
ANGPTL3 deficiency associates with the expansion of regulatory T cells with reduced lipid content
Grimaldos, A. P., Pacella, I., Bini, S., Tucci, G., Cammarata, I., Costanzo, A. D., Minicocci, I., D’Erasmo, L., Arca, M., & Piconese, S. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.09.014 · Cited by 7
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 7
Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon?
Hegele, R. A. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae068 · Cited by 7
Toth, P. P., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/216960 · Cited by 7
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
Biswas, A., Arshid, S., Kristensen, K. K., Jørgensen, T. J. D., & Ploug, M. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100745 · Cited by 6
New therapeutic approaches for the treatment of hypertriglyceridemia
Gouni‐Berthold, I., & Schwarz, J. (2022) · Herz · doi:10.1007/s00059-022-05113-x · Cited by 6
The era of targeted therapy for hyperlipidemia
Чубыкина, У. В., Tyurina, A. V., & Владиславович, Е. М. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6038 · Cited by 6
Adrenoceptor‐related decrease in serum triglycerides is independent of PPAR α activation
Konstandi, M., Kypreos, K. E., Matsubara, T., Xepapadaki, E., Shah, Y. M., Krausz, K. W., Andriopoulou, C. E., Kofinas, A., & Gonzalez, F. J. (2019) · FEBS Journal · doi:10.1111/febs.14966 · Cited by 6
Surma, S., Romańczyk, M., & Filipiak, K. J. (2021) · Folia Cardiologica · doi:10.5603/fc.2021.0005 · Cited by 6
Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3
Blackburn, N. B., Meikle, P. J., Peralta, J. M., Kumar, S., Leandro, A. C., Bellinger, M. A., Giles, C., Huynh, K., Mahaney, M. C., Göring, H. H. H., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003232 · Cited by 6
ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting
Weng, S., Ding, C., Lin, J., & Chai, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1706091 · Cited by 5
Maidman, S. D., & Rosenson, R. S. (2025) · BioDrugs · doi:10.1007/s40259-025-00731-3 · Cited by 7
Qiu, Y., Song, B., Yin, Z., Wang, M., Tao, Y., Xie, M., Duan, A., Chen, Z., Si, K., & Wang, Z. (2024) · European Stroke Journal · doi:10.1177/23969873241265019 · Cited by 5
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Genomic Strategies Toward Identification of Novel Therapeutic Targets
Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 5
Self-citationZhang, Y.-J., Zhang, L., Feng, F., & Cao, Q. (2021) · Disease Markers · doi:10.1155/2021/2863856 · Cited by 5
Ahn, J. E., Terra, S. G., & Liu, J. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12969 · Cited by 5
Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist
Girelli, D., Busti, F., Marchi, G., Martinelli, N., & Olivieri, O. (2018) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1810-5 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
ANGPTL3 Mutations in Unrelated Chinese Han Patients with Familial Hypercholesterolemia
Yang, Y., Yang, S., Jiao, X., Li, J., Zhu, M., Wang, L., & Qin, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190228000932 · Cited by 5
Concerns on the Genetic or Therapeutic Antagonism of ANGPTL3
Luo, F., Guo, Y., Fang, Z., & Li, X. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.076 · Cited by 5
Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3
Landmesser, U., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa790 · Cited by 5
Andersson, D. P., Littmann, K., Kindborg, G., Eklund, D., Sejersen, K., Yan, J., Hogling, D. E., Parini, P., & Brinck, J. W. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae010 · Cited by 4
Dyslipidemia and ANGPTL8 evaluation in young females with Type 1 diabetes mellitus
Mohammedsaeed, W. M., & Binjawhar, D. N. (2024) · Endocrine · doi:10.1007/s12020-024-03909-x · Cited by 4
Emerging therapies for refractory hypercholesterolemia: a narrative review
Pawlos, A., Khoury, É., & Gaudet, D. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2367860 · Cited by 4
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
Mansoor, T., Nambi, V., Parikh, S. S., Misra, A., Ismayl, M., Sullivan, C., Sperling, L. S., Virani, S. S., Rifai, M. A., Koshy, S. K. G., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00748-7 · Cited by 4
Erbasan, E., Aliciaslan, M., Erendor, F., Şanlioğlu, A. D., & Şanlıoğlu, S. (2025) · Gene Therapy · doi:10.1038/s41434-025-00575-0 · Cited by 5
Walker, S. G., Chen, Y., Sylvers-Davie, K. L., Dou, A., Zhen, Y., Qian, Y., Wen, Y., Ehsani, M. E., Smith, S. A., Thapa, R., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.197827 · Cited by 4
Low Cholesterol due to APOB Variants: Exploring the Balance Between Liver and Cardiovascular Risk
Costanzo, A. D., Pirona, I., Buonaiuto, S., Covino, S., Maiorca, C., Bini, S., Tramontano, D., Minicocci, I., Baratta, F., Colonna, V., et al. (2026) · Liver International · doi:10.1111/liv.70515 · Cited by 4
Natalí, L., de la Cruz-Thea, B., Godino, A., Conde, C. B., Peinado, V. I., & Musri, M. M. (2026) · Biomolecules · doi:10.3390/biom16010173 · Cited by 5
Imran, M., Bhoyar, R. C., Jain, A. K., Sahana, S., Rophina, M., Arvinden, V. R., Senthivel, V., Divakar, M. K., Mishra, A., Jolly, B., et al. (2023) · Human Gene · doi:10.1016/j.humgen.2023.201252 · Cited by 4
Hypertriglyceridemia – a new and important present
Васильевна, Ц. О., Apartseva, N. E., & As, A. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-4-99-111 · Cited by 4
Bian, X., Zhang, Y., Shao, M., Li, J., Ge, J., Li, Z., Peng, H. Y., & Zhang, M. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001361 · Cited by 4
Pan, Z., Zaman, M. A., Kalsoom, S., & Zhang, Y. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2423724 · Cited by 4
Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 4
Putative medicines that mimic mutations
Kathiresan, S. (2017) · Nature · doi:10.1038/nature23544 · Cited by 4
Self-citationThe year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx766 · Cited by 4
Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline
Xu, J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053489 · Cited by 4
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
ANGPTL3 deficiency protects from CAD
Fernández-Ruíz, I. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.67 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Genest, J. J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.015 · Cited by 14
ANGPTL3 targeting: The power of versatile lipid-lowering
Pessentheiner, A. R., Ramms, B., & Gordts, P. L. S. M. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.002 · Cited by 5
Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease
Natarajan, P. (2024) · New England Journal of Medicine · doi:10.1056/nejme2405647 · Cited by 4
Self-citationLi, W., Wang, Y., Huang, R., Feng, L., Xu, G.-X., Wang, W., & Xue, S. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03759-5 · Cited by 3
Watts, G. F., Scott, R., Sullivan, D., BAKER, J., Clifton, P. M., Hamilton, J., Given, B. D., Melquist, S., Zhou, R., Gaudet, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04307-8 · Cited by 3
Kršek, A., Batičić, L., & Tokmadžić, V. S. (2024) · Cardiogenetics · doi:10.3390/cardiogenetics14030012 · Cited by 4
Zambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Elevated triglycerides: A matter of the heart and pancreas
Blom, D. J. (2018) · South African Medical Journal · doi:10.7196/samj.2018.v108i4.13235 · Cited by 3
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 3
Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias
Watts, G. F., Chan, D. C., & Raal, F. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00027-3 · Cited by 3
Wu, T.-C., Hsu, B., Kuo, C., Wang, C., & Tsai, J. (2023) · Life · doi:10.3390/life14010018 · Cited by 3
Wu, D., Liu, J., Yang, X., Wu, Z., Wang, T., & Xiao, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31520 · Cited by 3
New Biotechnological Treatments for Lipid Disorders
Valencia‐Enciso, N., & Mendivil, C. O. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.18002577 · Cited by 3
Hipotrigliceridemias/hipolipidemias
Martínez‐Hervás, S., Real-Collado, J. T., & Ascaso-Gimilio, J. F. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.12.011 · Cited by 3
Low LDL Cholesterol Is Not an Independent Risk Factor for Hepatic Steatosis
Mchenry, S. A., Awad, A., Kozlitina, J., Stitziel, N. O., & Davidson, N. O. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07980-8 · Cited by 3
Self-citationANGPTL3 and ANGPTL8 in Thai subjects with hyperalphalipoproteinemia and severe hypertriglyceridemia
Kaewkrasaesin, C., Chatchomchuan, W., Muanpetch, S., & Khovidhunkit, W. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.08.059 · Cited by 3
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Nordestgaard, B. G., & Varbo, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_8 · Cited by 3
Rader, D. J., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00001-9 · Cited by 3
Self-citationCan one overcome “unhealthy genes”?
Lazarte, J., & Hegele, R. A. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0099-2 · Cited by 3
DeRoo, L. A., Abbas, M., Goodney, G. A., Lindsey, M. L., Oliver, A. F., Le, H., Oteng, A.-B., & Gaye, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.12.607634 · Cited by 3
Pirillo, A., Casula, M., Baragetti, A., & Catapano, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00001-7 · Cited by 3
Molecular diagnostics of familial hypercholesterolemia in Russia: yesterday, today and tomorrow
Zakharova, F. M., Мандельштам, М. Ю., Bogoslovskaya, T. Y., & Vasiliev, V. B. (2024) · Medical academic journal · doi:10.17816/maj630505 · Cited by 2
Li, W., Li, H., Guo, Z., Yan, P., Shen, Y., & Chen, Y. (2025) · Water Research · doi:10.1016/j.watres.2025.125125 · Cited by 2
Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5
Yang, Y., Smith, S. A., Chen, Y. Q., Li, H., Zhen, E. Y., Sloan, J. H., Siegel, R. W., Qian, Y., Wen, Y., Jung, H., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101050 · Cited by 2
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease
Davidson, N. O. (2026) · Circulation Research · doi:10.1161/circresaha.126.327269 · Cited by 2
Arca, M., Björnson, E., D’Erasmo, L., Costanzo, A. D., Bini, S., Minicocci, I., Tramontano, D., Covino, S., Ciarlo, G., Lombardi, M., et al. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70124 · Cited by 2
Baya, N. A., Lassen, F. H., Hill, B., Venkatesh, S. S., Currant, H., Lindgren, C. M., & Palmer, D. S. (2026) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2026.05.013 · Cited by 2
Bitencourt, I. C., Zimerman, A., & Marston, N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01441-z · Cited by 2
Муратович, Н. А., & Витальевна, К. К. (2024) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x305291240715112812 · Cited by 2
ANGPTL3 regulates the peroxisomal translocation of SmarcAL1 in response to cell growth states
Nagai, T. H., Mizoguchi, T., Wang, Y., Deik, A., Bullock, K. H., Clish, C. B., & Xu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-89552-6 · Cited by 2
Tran, H. H.-V., Thu, A., Twayana, A. R., Fuertes, A., Gonzalez, M., Basta, M., James, M., Mahadevaiah, A., Mehta, K. A., Islek, D., et al. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000976 · Cited by 2
Mango, G., Osti, N., Udali, S., Vareschi, A., Malerba, G., Giorgetti, A., Pizzolo, F., Friso, S., Girelli, D., Olivieri, O., et al. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.06.001 · Cited by 2
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Wang, H., Hu, X., Zhang, Y., Zhu, A., Fan, J., Wu, Z., Wang, X., Hu, W., & Ju, D. (2024) · Inflammation Research · doi:10.1007/s00011-024-01941-1 · Cited by 2
Self-citationAdjusting for medication status in genome-wide association studies
Chong, A., Kintu, C., Cho, Y., Fatumo, S., Torres, J., Smith, G. D., Gaunt, T. R., & Hemani, G. (2026) · PLoS Genetics · doi:10.1101/2024.02.19.24303028 · Cited by 2
Aghasizadeh, M., Nosrati, M., Saberi‐Karimian, M., Safarian, H., Asadiyan‐Sohan, P., Akbarpour, E., Sahebkar, A., Avan, A., Ferns, G. A., Kazemi, T., et al. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23980 · Cited by 2
Clinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
RNA therapies for cardiovascular disease
Laina, A., Vlachogiannis, N. I., Stamatelopoulos, K. S., & Stellos, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822546-2.00003-4 · Cited by 2
What is really new in triglyceride guidelines?
Hussain, A., Rifai, M. A., Hermel, M., Slipczuk, L. N., & Virani, S. S. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000802 · Cited by 2
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Working towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
Lian, S.-H., Hsu, B., Wang, J., & Chen, M. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_49_21 · Cited by 2
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00125-0 · Cited by 2
Pediatric Hypertriglyceridemia: Lipoprotein Metabolism, Etiology, and Management
Moriyama, H., & Ham, J. N. (2025) · Current Pediatrics Reports · doi:10.1007/s40124-025-00349-7 · Cited by 2
Hirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Ohara, M., Terasaki, M., Ito, Y., Yamagishi, S.-I., & Mori, Y. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65941 · Cited by 1
Meghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1
CRISPR-Cas9 gene therapy in dyslipidemia: a leap into the future?
Pande, S. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag019 · Cited by 1
RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside
Ali, I., Qiu, J., Cheang, W. S., Wang, G., & Xu, S. (2026) · Research · doi:10.34133/research.1288 · Cited by 1
Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels
Hegele, R. A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671686 · Cited by 1
In vivo base editing of Asgr1 reduces blood lipids in mice
Agrahari, G., Nguyen, N. T. K., Li, M., Zhang, C., Xu, J., Zhang, J., Chen, Y. E., & Han, R. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.020 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 1
Metadata
- Authors
- Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., Nomura, A., Erdmann, J., Schunkert, H., Samani, N. J., Kraus, W. E., Shah, S. H., Yu, B., Boerwinkle, E., Rader, D. J., Gupta, N., Frossard, P. M., Rasheed, A., Danesh, J., Lander, E. S., Gabriel, S., Saleheen, D., Musunuru, K., & Kathiresan, S.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Harvard University (US)
- Institute for Integrative and Experimental Genomics (DE)
- German Centre for Cardiovascular Research (DE)
- University of Leicester (GB)
- Duke University (US)
- Baylor College of Medicine (US)
- University of Pennsylvania (US)
- Center for Non-Communicable Diseases (PK)
- University of Cambridge (GB)
- Corresponding author
- Stitziel, Nathan O.
- ORCID
- Stitziel, Nathan O.
- Khera, Amit V.
- Bierhals, Andrew J.
- Sperry, Alexandra E.
- Natarajan, Pradeep
- Klarin, Derek
- Emdin, Connor A.
- Zekavat, Seyedeh M.
- Nomura, Akihiro
- Erdmann, Jeanette
- Schunkert, Heribert
- Samani, Nilesh J.
- Kraus, William E.
- Shah, Svati H.
- Yu, Bing
- Boerwinkle, Eric
- Rader, Daniel J.
- Gupta, Namrata
- Danesh, John
- Lander, Eric S.
- Gabriel, Stacey
- Saleheen, Danish
- Musunuru, Kiran
- Kathiresan, Sekar
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 69
- Issue
- 16
- Pages
- 2054-2063
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC5404817
- OpenAlex
- W2604768034
- Cited by
- 467
- References
- 45
- Citations by year
- 2026: 38 · 2025: 39 · 2024: 46 · 2023: 58 · 2022: 57 · 2021: 70 · 2020: 44 · 2019: 36 · 2018: 54 · 2017: 23
- FWCI
- 33.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
- Apollo
- Funders
- Harvard Catalyst
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- National Institutes of Health (5t32hl007734-30, KL2TR001100)
- Medical Research Council (MR/L003120/1)
- National Heart, Lung, and Blood Institute (R01HL127564, K08HL114642, R33HL120781, R21HL120781, T-32HL007734, RC2HL101834, R01HL118744, R01HL131961)
- National Human Genome Research Institute (UM1HG008895, U54HG003067, UM1HG008853)
- Fogarty International Center (RC1TW008485)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- ANGPTL3, coronary artery disease, loss-of-function mutations, myocardial infarction, triglycerides, LDL cholesterol, genetic risk, heterozygous carriers, hypolipidemic effect, first-degree relatives, loss-of-function screening
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adult, Animals, Coronary Artery Disease, Female, Humans, Lipids, Male, Mice, Inbred C57BL, Middle Aged, Myocardial Infarction, Risk Factors, Case-Control Studies, Mice, Knockout, Mutation, Missense, Angiopoietins, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
